TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8181328

Group type: EXPERIMENTAL
Intervention: Combination of ipratropium and albuterol
Number of subjects: 534

Group type: COMPARATOR
Intervention: Ipratropium
Number of subjects: 534

Group type: COMPARATOR
Intervention: Albuterol
Number of subjects: 534
Study: 3695494

Group type: EXPERIMENTAL
Intervention: Fluoxymesterone (5 mg p.o. b.i.d.) for 3 days before and on the day of chemotherapy
Number of subjects: 75

Group type: COMPARATOR
Intervention: Cyclic i.v. chemotherapy with cytoxan, adriamycin and 5-fluorouracil
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control arm (no androgen priming)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Stimulation arm (with androgen priming)
Number of subjects: 75
Study: 30539767

Group type: EXPERIMENTAL
Intervention: Customized moderate intensity 12-week aerobic or weight-bearing exercise program
Number of subjects: 17
Study: 26636547

Group type: EXPERIMENTAL
Intervention: Reduction in cannabis use
Number of subjects: 332
Study: 24968966

Group type: EXPERIMENTAL
Intervention: taVNS
Number of subjects: 72
Study: 23379542

Group type: EXPERIMENTAL
Intervention: 8-week comprehensive lifestyle modification program (CLMP) in addition to standard care
Number of subjects: 29

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 29
Study: 21489065

Group type: EXPERIMENTAL
Intervention: Intervention video identifying the artificial nature of media images
Number of subjects: 127

Group type: COMPARATOR
Intervention: Control images (non-thin models)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Ultra-thin models exposure without intervention
Number of subjects: 127
Study: 18691861

Group type: EXPERIMENTAL
Intervention: Budesonide-containing treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Formoterol treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline St George's Respiratory Questionnaire (SGRQ) total score
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 36-item short-form health survey (SF-36) scores
Number of subjects: 0
Study: 17318445

Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation and linear lesions
Number of subjects: 100

Group type: COMPARATOR
Intervention: Pulmonary vein isolation alone
Number of subjects: 100
Study: 12668406

Group type: EXPERIMENTAL
Intervention: Exposure therapy
Number of subjects: 375

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Sertraline plus exposure therapy
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Sertraline alone
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Exposure therapy alone
Number of subjects: 375
Study: 10708933

Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg/day)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Atenolol and Propranolol
Number of subjects: 10
Study: 9543786

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (3 doses)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Primary vaccination (3 doses)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Booster vaccination (1 dose) after vaccination 7 years earlier
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group with immune status based on past infection (3 doses)
Number of subjects: 26
Study: 1556672

Group type: EXPERIMENTAL
Intervention: Beighton's, Carter's and Rotés' HMS scores
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: New scale for defining HMS
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Major HMS items
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Basic set of criteria to define HMS
Number of subjects: 114
Study: 3310339

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 52

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 52
Study: 30701736

Group type: EXPERIMENTAL
Intervention: Nicorandil (30 mg/day for 2 days and 1 day before PCI, 20 mg 2 hours before PCI, 10 mg 6 hours after PCI)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Standard therapy (control group)
Number of subjects: 88
Study: 27296040

Group type: EXPERIMENTAL
Intervention: Dose-escalated concurrent chemoradiotherapy (CRT) with tumor doses of 63 to 73 Gy in 30 once-daily fractions over 6 weeks with 2 concurrent cycles of cisplatin and vinorelbine.
Number of subjects: 84
Study: 23868679

Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Aerobic plus Resistance Training (AT + RT)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Leisure Physical Activity (LPA)
Number of subjects: 72
Study: 22506530

Group type: EXPERIMENTAL
Intervention: Printed toolkit
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Toolkit and a brief guide to the toolkit's content
Number of subjects: 315

Group type: COMPARATOR
Intervention: Wait-list condition
Number of subjects: 315
Study: 19944650

Group type: EXPERIMENTAL
Intervention: ALO-01 (morphine sulfate and naltrexone hydrochloride)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Extended-release morphine sulfate (ERMS)
Number of subjects: 113

Group type: COMPARATOR
Intervention: ALO-01 and ERMS
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: ALO-01
Number of subjects: 113
Study: 18678581

Group type: EXPERIMENTAL
Intervention: Nature art (art images dominated by natural vegetation, flowers or water)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 225
Study: 16946602

Group type: EXPERIMENTAL
Intervention: Topical fluoride interventions
Number of subjects: 15

Group type: COMPARATOR
Intervention: Cluster-randomized trials
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sample size calculation
Number of subjects: 15
Study: 12659989

Group type: EXPERIMENTAL
Intervention: Trimethazidine (60 mg) + Diltiazem (90 mg)
Number of subjects: 50
Study: 11126034

Group type: EXPERIMENTAL
Intervention: meperidine (0.7 mg/kg) or midazolam (0.035 mg/kg) intravenously
Number of subjects: 50

Group type: COMPARATOR
Intervention: no medication (control group)
Number of subjects: 50
Study: 9366538

Group type: EXPERIMENTAL
Intervention: Ureteric jet index (calculated from colour Doppler ultrasound)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Scintigraphic index (found using Patlak‐Rutland graphical analysis)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Comparison of jet index and scintigraphic index
Number of subjects: 31

Group type: COMPARATOR
Intervention: Discrepancies in scores
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Impact of renal artery stenosis
Number of subjects: 31
Study: 1388878

Group type: EXPERIMENTAL
Intervention: 200 IU nHuIFN alpha once daily orally for 6 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 3902200

Group type: COMPARATOR
Intervention: CMF (cyclophosphamide, methotrexate, and 5‐fluorouracil)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: CMF and tamoxifen (TMX)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: CMF and medroxyprogesterone (MAP)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Adriamycin (doxorubicin) (ADX) vincristine (VCR) and TMX
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Adriamycin (doxorubicin) (ADX) vincristine (VCR) and MAP
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Responders to both treatments
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Survival
Number of subjects: 117
Study: 28830853

Group type: EXPERIMENTAL
Intervention: Sugarsquare (web-based patient portal)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 105
Study: 26133200

Group type: EXPERIMENTAL
Intervention: Partially covered SEMS
Number of subjects: 103

Group type: COMPARATOR
Intervention: Uncovered SEMS
Number of subjects: 103
Study: 23768685

Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiotherapy (CRT)
Number of subjects: 799

Group type: EXPERIMENTAL
Intervention: Postoperative chemoradiotherapy (CRT)
Number of subjects: 799

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (CRT)
Number of subjects: 799

Group type: EXPERIMENTAL
Intervention: Acute organ toxicity
Number of subjects: 799

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 799
Study: 21635992

Group type: EXPERIMENTAL
Intervention: Varenicline 1 mg, BID for 12 weeks
Number of subjects: 588

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 588
Study: 19840695

Group type: EXPERIMENTAL
Intervention: Basic tailored intervention (targeted psychosocial determinants)
Number of subjects: 1971

Group type: EXPERIMENTAL
Intervention: Environmentally tailored intervention (intervention-plus)
Number of subjects: 1971

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 1971
Study: 16461961

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 31897

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 31897

Group type: COMPARATOR
Intervention: Chlorthalidone
Number of subjects: 31897
Study: 16117955

Group type: EXPERIMENTAL
Intervention: Lambdacyhalothrin residual house spraying (25 mg/m²)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 39
Study: 10773777

Group type: EXPERIMENTAL
Intervention: Polysymptomatic (PS) cases
Number of subjects: 44

Group type: COMPARATOR
Intervention: Monosymptomatic (MS) cases
Number of subjects: 44
Study: 9596981

Group type: EXPERIMENTAL
Intervention: Phenylalanine 1 g/d (58 subjects)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo 1 g/d (38 subjects)
Number of subjects: 96
Study: 8257205

Group type: EXPERIMENTAL
Intervention: Low power laser treatment (12 J/cm2 for 30 s, 12 treatments over four weeks)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Sham laser treatment
Number of subjects: 25
Study: 3928053

Group type: EXPERIMENTAL
Intervention: Multiple insulin injections
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Insulin pump
Number of subjects: 0
Study: 29723339

Group type: EXPERIMENTAL
Intervention: Concentrated growth factor (CGF)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Acellular dermal matrix (ADM)
Number of subjects: 20
Study: 28253079

Group type: EXPERIMENTAL
Intervention: Yohimbine (α2‐adrenoceptor antagonist)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both drugs (Yohimbine and Hydrocortisone)
Number of subjects: 0
Study: 25768023

Group type: EXPERIMENTAL
Intervention: Telecare intervention (data uploaded daily to a nurse-led monitoring station)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 171
Study: 23311705

Group type: EXPERIMENTAL
Intervention: Active TENS
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo TENS
Number of subjects: 74
Study: 21614630

Group type: EXPERIMENTAL
Intervention: Patients with documented allergies
Number of subjects: 521

Group type: EXPERIMENTAL
Intervention: Patients with accurate allergy documentation
Number of subjects: 521

Group type: COMPARATOR
Intervention: Patients with no allergy documentation
Number of subjects: 521
Study: 18686184

Group type: EXPERIMENTAL
Intervention: Smokeless tobacco plus group support
Number of subjects: 263

Group type: COMPARATOR
Intervention: Group support only
Number of subjects: 263
Study: 16497687

Group type: EXPERIMENTAL
Intervention: Effective CPAP
Number of subjects: 23

Group type: COMPARATOR
Intervention: Sham CPAP
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Baseline OSA patients
Number of subjects: 23
Study: 14600550

Group type: EXPERIMENTAL
Intervention: Exercise training (EX): 50 min of treadmill walking at 65% of heart rate reserve for 10 consecutive days
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Exercise training (EX)
Number of subjects: 32
Study: 9862844

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: UDCA
Number of subjects: 0
Study: 8554251

Group type: COMPARATOR
Intervention: Placebo (10 g of lactulose)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Lactulose
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Psyllium (fermentable fiber)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Methylcellulose (nonfermentable fiber)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Both fiber preparations and lactulose
Number of subjects: 25
Study: 1864100

Group type: EXPERIMENTAL
Intervention: Terbutaline (0.5 mg) inhaled with positive expiratory pressure (PEP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Terbutaline (0.5 mg) inhaled without PEP
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo spray inhaled with PEP
Number of subjects: 0
Study: 6191298

Group type: EXPERIMENTAL
Intervention: VAT pacing
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: V-CWS-T pacing
Number of subjects: 14

Group type: COMPARATOR
Intervention: VOO mode at 70 beats per minute
Number of subjects: 14
Study: 29417384

Group type: EXPERIMENTAL
Intervention: Agave fructans (96 mg/bw for 12 weeks)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Maltodextrin (placebo for 12 weeks)
Number of subjects: 28
Study: 26997623

Group type: EXPERIMENTAL
Intervention: Protein isolates (60 g/day)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Maltodextrin (60 g/day)
Number of subjects: 79
Study: 24296850

Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study: 22964958

Group type: EXPERIMENTAL
Intervention: Aprepitant
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 20581351

Group type: COMPARATOR
Intervention: Vitamin C (1 g/day) and Vitamin E (400 IU/day) supplementation during pregnancy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin C preincubation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin C alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: TNF incubation
Number of subjects: 0
Study: 17962619

Group type: EXPERIMENTAL
Intervention: Immediate intervention with darbepoetin alfa (300 microg every 3 weeks)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Observation group (delayed intervention)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Immediate intervention with darbepoetin alfa
Number of subjects: 201

Group type: COMPARATOR
Intervention: Delayed intervention subgroup (received darbepoetin alfa later)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Delayed intervention subgroup
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 201
Study: 16287955

Group type: EXPERIMENTAL
Intervention: Edifoligide
Number of subjects: 3014

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3014
Study: 12121931

Group type: EXPERIMENTAL
Intervention: 6 mg/kg i.v. b.i.d. on day 1 followed by 3 mg/kg i.v. b.i.d. on days 2 to 7, then switched to 200 mg orally b.i.d. for days 8 to 14
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 6 mg/kg i.v. b.i.d. on day 1 followed by 5 mg/kg i.v. b.i.d. on days 2 to 7, then switched to 400 mg orally b.i.d. for days 8 to 14
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 6 mg/kg i.v. b.i.d. on day 1 followed by 4 mg/kg i.v. b.i.d. on days 2 to 7, then switched to 300 mg orally b.i.d. for days 8 to 14
Number of subjects: 42

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Voriconazole treatment
Number of subjects: 42
Study: 10633514

Group type: EXPERIMENTAL
Intervention: Computerized anesthesia delivery system
Number of subjects: 57

Group type: COMPARATOR
Intervention: Traditional anesthesia delivery system
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 57
Study: 7861219

Group type: EXPERIMENTAL
Intervention: ranitidine (50 mg every 6 hours)
Number of subjects: 101

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 101
Study: 2019922

Group type: EXPERIMENTAL
Intervention: Cow milk formula without added iron
Number of subjects: 854

Group type: EXPERIMENTAL
Intervention: Human milk
Number of subjects: 854

Group type: EXPERIMENTAL
Intervention: Cow milk formula with added iron
Number of subjects: 854

Group type: EXPERIMENTAL
Intervention: Iron dextran injection
Number of subjects: 854
Study: 7181805

Group type: EXPERIMENTAL
Intervention: Benactyzine hydrochloride (intramuscular administration)
Number of subjects: 6
Study: 31907009

Group type: EXPERIMENTAL
Intervention: Clinical Pharmacy Practice Model (CPPM)
Number of subjects: 720

Group type: COMPARATOR
Intervention: Usual care process
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: CPPM
Number of subjects: 720
Study: 31533151

Group type: EXPERIMENTAL
Intervention: Amniotic Suspension Allograft (ASA)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Hyaluronic Acid (HA)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 200
Study: 28196583

Group type: EXPERIMENTAL
Intervention: Opportunistic screening through pulse palpation
Number of subjects: 7000

Group type: COMPARATOR
Intervention: Active search for symptomatic patients
Number of subjects: 7000
Study: 26782527

Group type: EXPERIMENTAL
Intervention: Short ultrasound (10 min)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Long ultrasound (20 min)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 24463662

Group type: COMPARATOR
Intervention: 25-hydroxyvitamin D concentrations <30 nmol/L
Number of subjects: 792

Group type: EXPERIMENTAL
Intervention: 25-hydroxyvitamin D concentrations 50-74 nmol/L
Number of subjects: 792

Group type: EXPERIMENTAL
Intervention: 25-hydroxyvitamin D concentrations ≥75 nmol/L
Number of subjects: 792

Group type: EXPERIMENTAL
Intervention: 25-hydroxyvitamin D concentrations ≥50 nmol/L in white women
Number of subjects: 792

Group type: EXPERIMENTAL
Intervention: 25-hydroxyvitamin D concentrations ≥50 nmol/L in nonobese women
Number of subjects: 792
Study: 21788541

Group type: EXPERIMENTAL
Intervention: Nurse-led transitional care program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other hospitals within the Baylor Health Care System (control)
Number of subjects: 0
Study: 18829689

Group type: EXPERIMENTAL
Intervention: Secondary care group (multi-disciplinary assessment in a day hospital)
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: Primary care group (nurse-led assessment and targeted referral)
Number of subjects: 505

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 505
Study: 17317184

Group type: EXPERIMENTAL
Intervention: Breast MRI
Number of subjects: 491

Group type: COMPARATOR
Intervention: XRM (mammography +/‐ ultrasound)
Number of subjects: 491
Study: 15220883

Group type: EXPERIMENTAL
Intervention: Arthroscopic rotator cuff repair with arthroscopic subacromial decompression (group 1)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Arthroscopic rotator cuff repair without arthroscopic subacromial decompression (group 2)
Number of subjects: 93
Study: 10893378

Group type: EXPERIMENTAL
Intervention: Atropine (0.01 mg/kg body weight, IM injection)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate (0.005 mg/kg, IM injection)
Number of subjects: 217

Group type: COMPARATOR
Intervention: Saline solution placebo (approximately 2 mL, IM injection)
Number of subjects: 217
Study: 8941060

Group type: EXPERIMENTAL
Intervention: FSH (75 IU) + GH (0.1 IU/kg IM for 3 days)
Number of subjects: 24

Group type: COMPARATOR
Intervention: FSH (75 IU)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 24

Group type: COMPARATOR
Intervention: GH alone
Number of subjects: 24
Study: 1546817

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (110, 220, or 440 microgram)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (440 microgram)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide
Number of subjects: 304

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 304
Study: 2408513

Group type: EXPERIMENTAL
Intervention: Atracurium (1 in 1,000 and 1 in 10,000)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Vecuronium (1 in 1,000)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tubocurarine (1 in 1,000)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Thiopentone (1 in 100)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.9% saline control
Number of subjects: 60
Study: 2884862

Group type: EXPERIMENTAL
Intervention: Pirmenol 50 or 100 mg intravenously
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 28952457

Group type: EXPERIMENTAL
Intervention: Face-to-face education (10 minutes)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No specific education
Number of subjects: 0
Study: 27831492

Group type: EXPERIMENTAL
Intervention: Withdrawal of active treatment (WAT)
Number of subjects: 2779
Study: 26608649

Group type: EXPERIMENTAL
Intervention: Weight loss program (calorie restriction of 100-150 kcal/day, fat-free vegetables, salt diet, optimum physical activity)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Weight loss program
Number of subjects: 97
Study: 23673893

Group type: EXPERIMENTAL
Intervention: HIV risk-reduction intervention
Number of subjects: 349
Study: 21420106

Group type: EXPERIMENTAL
Intervention: 24 °C bypass temperature
Number of subjects: 66
Study: 18499600

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine 0.5 microg/kg
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine 1 microg/kg
Number of subjects: 96

Group type: COMPARATOR
Intervention: Oral midazolam 0.5 mg/kg
Number of subjects: 96
Study: 16586550

Group type: EXPERIMENTAL
Intervention: Proton-pump inhibitor (omeprazole or lansoprazole), clarithromycin, bismuth citrate and tinidazole
Number of subjects: 48

Group type: COMPARATOR
Intervention: Protective agent of gastric mucosa (tepretone)
Number of subjects: 48
Study: 14623508

Group type: EXPERIMENTAL
Intervention: Midwife education and support for smoking behaviour change
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Midwife's approach to smoking cessation
Number of subjects: 27
Study: 10882825

Group type: EXPERIMENTAL
Intervention: Sucralose (125mg/day for weeks 1-3, 250mg/day for weeks 4-7, 500mg/day for weeks 8-12)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Fructose (50g/day)
Number of subjects: 86
Study: 8808130

Group type: EXPERIMENTAL
Intervention: 50 mg fluvoxamine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 100 mg fluvoxamine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 75 mg dothiepin
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12